Focused Issue on Stem Cell Derived Chemotherapy Resistance of Cancer

Posted On 2018-03-26 15:57:51


This focused issue on “Stem Cell Derived Chemotherapy Resistance of Cancer” is edited by Shuhang Wang, Peking University Cancer Hospital and Institute, Beijing, China.

Dr. Shuhang Wang obtained her master's degree in oncology from Peking University School of Medicine in 2009. She is currently an oncologist in Peking University Cancer Hospital, Beijing, China. Dr. Wang’s main research directions are multidisciplinary, individualized comprehensive treatment of lung cancer and translational medicine research of lung cancer. She specializes in research on individualized and multidisciplinary treatment of lung cancer based on genotyping.

Focused issue outline:
  1. Voltage-dependent calcium channel α2δ1 subunit-mediated chemotherapy resistance in small cell lung cancer
  2. Strategies of conquering acquired chemotherapy resistance regarding cancer stem cells
  3. The role of microRNA in overcoming cancer stem cell derived chemo-resistance in colorectal cancer
  4. How micro-RNA impairs chemo-resistance of human osteosarcoma stem cells
  5. Using BMI1 positive cancer stem cells overcome chemo-resistance in squamous cell carcinoma
  6. EMP2 for endometrial cancer stem cells
  7. Chemo-resistance of glioblastoma growth after
  8. Cancer stem cells and epithelial mesenchymal transition in chemo-resistance of urothelial carcinoma
  9. Stem cell in chemo-resistance of acute myeloid leukaemia
  10. Stem cell in chemo-resistance of melanomas
  11. Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma
  12. PGE2-induced tumour repopulation and bladder cancer chemoresistance
  13. Notch and radioresistance of glioma
  14. Cancer stem cells and their microenvironment
  15. MET signaling of stem-like cells with response to EGFR inhibitors in colon cancer
  16. Tetraspanin 3 in drug resistance of acute myelogenous leukemia
  17. The histone demethylase KDM1A and drug resistance of MLL-AF9 leukemia
  18. HDAC1 and NANOG in multidrug resistance of immune edited tumor cells